Tag:
pancreatic cancer
Latest Headlines
Latest Headlines
Early pancreatic biomarker could spot killer disease
The diagnosis of pancreatic ductal adenocarcinoma is difficult and often the disease isn't spotted until it's advanced. University of California researchers have found a biomarker, PEAK1, that could help to spot the disease earlier.
Pancreatic cancer protein biomarker could predict outcomes
In research published in Nature , a team of researchers have found that if a gene is faulty, mice with pancreatic ductal adenocarcinoma are less likely to survive surgery.
Threshold Pharma lands $20M milestone from Merck KGaA
Threshold Pharmaceuticals reported this morning that Merck KGaA is handing over a $20 million milestone for a successful mid-stage study of their pancreatic cancer drug.
Survivin could be key to survival in pancreatic cancer
Survivin, a biomarker studied by researchers at Fox Chase Cancer Center, may help point out the patients who could respond to treatment.
Deadly mushroom defeats human pancreatic cancer in mice
Scientists in Germany working together from three separate institutions have harnessed the deadly death cap mushroom to stop pancreatic cancer in mice.
Cell-based pancreatic cancer vaccine increases survival
BioSante Pharmaceuticals' ( $BPAX ) shares rose 14% on the news its pancreatic cancer vaccine increased survival by around 60%.
BioSante shares surge on GVAX data for pancreatic cancer
Shares of BioSante ( $BPAX ) shot up more than 20% this morning after the developer heralded data showing improved survival rates in an early trial of GVAX for pancreatic cancer. The data is from a...
Threshold shares spike on positive IIb data for pancreatic cancer drug
Threshold Pharmaceuticals ( $THLD ) put out the word this morning that its experimental therapy TH-302 delayed the progression of advanced, aggressive pancreatic cancer by two months in a Phase IIb...
Threshold, Merck KGaA strike $525M licensing deal for promising cancer drug
The dealmakers at South San Francisco-based Threshold Pharmaceuticals ($THLD) have crafted a $525 million licensing pact with Merck KGaA covering its late-stage cancer drug TH-302. Threshold snagged
Infinity craters after lead drug flunks PhII cancer study
Infinity Pharmaceuticals' ( $INFI ) lead therapy failed a critical mid-stage hurdle as investigators moved to shut down a study for pancreatic cancer after the treatment in combination with a common
